

# Kow Chia Siang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6312934/publications.pdf>

Version: 2024-02-01

134  
papers

1,720  
citations

448610

19  
h-index

406436

35  
g-index

138  
all docs

138  
docs citations

138  
times ranked

3326  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of biochemical and safety parameters of regular kratom ( <i>Mitragyna speciosa</i> ) Tj ETQq1 1 0.784314 rgBT /Overlock	0.3	1
2	Early Oxygen Therapy may be Beneficial to Patients with COVID-19 and Underlying Pulmonary Diseases. Journal of Asthma, 2023, 60, 422-423.	0.9	2
3	Preadmission use of inhaled corticosteroids and risk of fatal or severe COVID-19: a meta-analysis. Journal of Asthma, 2022, 59, 787-790.	0.9	10
4	The use of remdesivir for the management of patients with moderate-to-severe COVID-19: a systematic review. Expert Review of Anti-Infective Therapy, 2022, 20, 211-229.	2.0	10
5	The Association Between the Use of Statins and Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-analysis. American Journal of Cardiovascular Drugs, 2022, 22, 167-181.	1.0	24
6	Use of Calcium Channel Blockers and the Risk of All-cause Mortality and Severe Illness in Patients With COVID-19: A Systematic Review and Meta-analysis. Journal of Cardiovascular Pharmacology, 2022, 79, 199-205.	0.8	4
7	Use of aspirin for primary prevention in patients with diabetes during the COVID-19 pandemic. Irish Journal of Medical Science, 2022, 191, 1667-1668.	0.8	2
8	Insulin therapy in patients with COVID-19. Acta Diabetologica, 2022, 59, 285-286.	1.2	0
9	Clinical outcomes of sofosbuvir-based antivirals in patients with COVID-19: a systematic review and meta-analysis of randomized trials. Expert Review of Anti-Infective Therapy, 2022, 20, 567-575.	2.0	6
10	Has it come to the time to recommend routine use of alirocumab in patients with acute coronary syndrome?. European Journal of Preventive Cardiology, 2022, 29, e77-e78.	0.8	0
11	IL-6 antagonists to replace systemic corticosteroids as the preferred anti-inflammatory therapy in patients with COVID-19?. Cytokine, 2022, 149, 155730.	1.4	2
12	Clinical outcomes of hypertensive patients with COVID-19 receiving calcium channel blockers: a systematic review and meta-analysis. Hypertension Research, 2022, 45, 360-363.	1.5	13
13	Amiodarone in COVID-19: let's not forget its potential for pulmonary toxicity. European Journal of Preventive Cardiology, 2022, 28, e52-e52.	0.8	1
14	The use of neutralizing monoclonal antibodies and risk of hospital admission and mortality in patients with COVID-19: a systematic review and meta-analysis of randomized trials. Immunopharmacology and Immunotoxicology, 2022, 44, 28-34.	1.1	16
15	Melatonin: Revisited Role as Vaccine Adjuvant During Outbreaks of COVID-19 Caused by the Delta Variant. Journal of NeuroImmune Pharmacology, 2022, 17, 425-426.	2.1	1
16	The effect of higher-intensity dosing of anticoagulation on the clinical outcomes in hospitalized patients with COVID-19: A meta-analysis of randomized controlled trials. Journal of Infection and Chemotherapy, 2022, 28, 257-265.	0.8	18
17	Physiological plausibility of lower viral load in patients with COVID-19 and olfactory/gustatory dysfunction. Clinical Otolaryngology, 2022, 47, 397-398.	0.6	1
18	Future of antivirals in COVID-19: The case of favipiravir. International Immunopharmacology, 2022, 103, 108455.	1.7	5

#	ARTICLE	IF	CITATIONS
19	The use of tenofovir in patients with COVID-19. HIV Medicine, 2022, 23, 807-808.	1.0	2
20	The effectiveness of BNT162b2 mRNA vaccine against COVID-19 caused by Delta variant of SARS-CoV-2: a systematic review and meta-analysis. Inflammopharmacology, 2022, 30, 149-157.	1.9	3
21	Effects of educational interventions on the smoking cessation service provided by community pharmacists: A systematic review. Research in Social and Administrative Pharmacy, 2022, , .	1.5	1
22	Metformin in COVID-19: clinical trials are needed to prove its benefits. Irish Journal of Medical Science, 2022, 191, 2641-2642.	0.8	2
23	Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure. Revista Clínica Española, 2022, , .	0.3	2
24	The effectiveness of mRNA-1273 vaccine against COVID-19 caused by Delta variant: A systematic review and meta-analysis. Journal of Medical Virology, 2022, 94, 2269-2274.	2.5	14
25	Metformin-based single pill drug combinations for type 2 diabetes in primary care England: A time trend analysis. Primary Care Diabetes, 2022, 16, 271-278.	0.9	2
26	Pattern of medication utilization in hospitalized patients with COVID-19 in three District Headquarters Hospitals in the Punjab province of Pakistan. Exploratory Research in Clinical and Social Pharmacy, 2022, 5, 100101.	0.6	8
27	Combination Therapy with CCBs and RAS Inhibitors to Counteract Endothelial Dysfunction in COVID-19. High Blood Pressure and Cardiovascular Prevention, 2022, , 1.	1.0	0
28	Risk of severe illness in patients infected with SARS-CoV-2 of Delta variant: a systematic review and meta-analysis. Infectious Diseases, 2022, 54, 614-617.	1.4	6
29	Use of sulforaphane in COVID-19: Clinical trials are needed. Molecular Immunology, 2022, 145, 78-79.	1.0	6
30	The effect of colchicine on mortality outcome and duration of hospital stay in patients with COVID-19: A meta-analysis of randomized trials. Immunity, Inflammation and Disease, 2022, 10, 255-264.	1.3	15
31	The effect of curcumin on the risk of mortality in patients with COVID-19: A systematic review and meta-analysis of randomized trials. Phytotherapy Research, 2022, 36, 3365-3368.	2.8	6
32	Angiotensin Receptor and Neprilysin Inhibitors for COVID-19 Treatment and Personalized Medicine?. OMICS A Journal of Integrative Biology, 2022, 26, 318-319.	1.0	0
33	Can COVID-19 vaccines improve cardiovascular outcomes?. Travel Medicine and Infectious Disease, 2022, 48, 102350.	1.5	3
34	Effects of Angiotensin II Receptor Blockers on the Risk of Mortality in Patients with COVID-19: An Updated Systematic Review and Meta-analysis of Randomized Trials. American Journal of Hypertension, 2022, 35, 763-764.	1.0	2
35	Management of Comedication in Hospitalized COVID-19 Patients With Atrial Fibrillation. Hospital Pharmacy, 2021, 56, 629-632.	0.4	0
36	Corticosteroid-related In-Hospital Hyperglycemia: Does It Negate Mortality Benefits in Coronavirus Disease 2019?. Clinical Infectious Diseases, 2021, 73, e2848-e2849.	2.9	10

#	ARTICLE	IF	CITATIONS
37	Social distancing and the use of PPE by community pharmacy personnel: Does evidence support these measures?. <i>Research in Social and Administrative Pharmacy</i> , 2021, 17, 456-459.	1.5	34
38	Could melatonin be used in COVID-19 patients with laryngopharyngeal reflux disease?. <i>Journal of Medical Virology</i> , 2021, 93, 92-93.	2.5	2
39	Pharmacologic therapeutic options for thromboprophylaxis in COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 29-30.	1.0	7
40	Pharmacological Management of Obese Patients with Type 2 Diabetes amid COVID-19 Pandemic. <i>Obesity Surgery</i> , 2021, 31, 413-414.	1.1	2
41	Interleukin-6 blockade with tocilizumab in COVID-19: Does it live up to its hype?. <i>Pulmonology</i> , 2021, 27, 86-87.	1.0	3
42	Consistency of recommendations from clinical practice guidelines for the management of critically ill COVID-19 patients. <i>European Journal of Hospital Pharmacy</i> , 2021, 28, 42-46.	0.5	8
43	Neurohormonal treatment in tako-tsubo cardiomyopathy precipitated by COVID-19. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 200-201.	0.4	0
44	Revascularization strategy in patients with acute ST-elevation myocardial infarction amid COVID-19 pandemic. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 772-773.	0.8	0
45	The use of antiplatelet agents for arterial thromboprophylaxis in COVID-19. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2021, 74, 114-115.	0.4	6
46	Are severe asthma patients at higher risk of developing severe outcomes from COVID-19?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 959-960.	2.7	15
47	Pharmacotherapeutic considerations for the management of diabetes mellitus among hospitalized COVID-19 patients. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 229-240.	0.9	14
48	Use of proton pump inhibitors and risk of adverse clinical outcomes from COVID-19: a meta-analysis. <i>Journal of Internal Medicine</i> , 2021, 289, 125-128.	2.7	31
49	Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 435-437.	0.8	10
50	Prasugrel over ticagrelor in non-ST-elevation acute coronary syndromes: is it justified?. <i>European Heart Journal</i> , 2021, 42, 2609-2610.	1.0	2
51	Macrolides for patients with COVID-19 and concurrent pertussis infection. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 99, 115245.	0.8	1
52	CYP2C19 Genotype-Guided Antiplatelet Therapy Among Asian Patients with Ischaemic Stroke. <i>Clinical Drug Investigation</i> , 2021, 41, 115-116.	1.1	2
53	Use of DPP-4 inhibitors in patients with COVID-19. <i>Acta Diabetologica</i> , 2021, 58, 245-246.	1.2	6
54	The use of combined hormonal contraceptives amid the COVID-19 pandemic. <i>European Journal of Contraception and Reproductive Health Care</i> , 2021, 26, 85-86.	0.6	3

#	ARTICLE	IF	CITATIONS
55	Prochlorperazine for nausea and vomiting accompanied COVID-19. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 524-525.	1.4	4
56	Effect of remdesivir on mortality in patients with COVID-19: A meta-analysis of randomized control trials. <i>Journal of Medical Virology</i> , 2021, 93, 1860-1861.	2.5	9
57	Azithromycin in patients with COVID-19: Friend or foe?. <i>Clinical Microbiology and Infection</i> , 2021, 27, 136-137.	2.8	5
58	Angiotensin-II receptor blockers or angiotensin converting enzyme inhibitors for the treatment of hypertension amid COVID-19 pandemic. <i>Expert Review of Cardiovascular Therapy</i> , 2021, 19, 99-100.	0.6	1
59	Use of potentially inappropriate medications among older outpatients and inpatients in a tertiary care hospital in Malaysia. <i>International Journal of Clinical Practice</i> , 2021, 75, e13714.	0.8	5
60	Revascularization in COVID-19 patients with renal infarction. <i>American Journal of Transplantation</i> , 2021, 21, 1345-1345.	2.6	0
61	The use of antimotility drugs in COVID-19 associated diarrhea. <i>Journal of Infection</i> , 2021, 82, e19.	1.7	9
62	Mortality risk with preadmission metformin use in patients with COVID-19 and diabetes: A meta-analysis. <i>Journal of Medical Virology</i> , 2021, 93, 695-697.	2.5	68
63	Colchicine as an adjunct to heparin for prophylaxis of venous thromboembolism in patients with COVID-19. <i>Rheumatology International</i> , 2021, 41, 677-678.	1.5	8
64	Persistent fatigue in patients with COVID-19. <i>Clinical Medicine</i> , 2021, 21, e117-e117.	0.8	2
65	Potential Drug-Drug Interactions Between Interleukin-6 Inhibitors and Pharmacologic Agents for Opioid Use Disorder. <i>primary care companion for CNS disorders, The</i> , 2021, 23, .	0.2	0
66	Insulin Treatment May Not Be Associated with Increased Mortality in Patients with COVID-19 and Concurrent Diabetes. <i>Endocrine Research</i> , 2021, 46, 51-52.	0.6	3
67	The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 1089-1094.	0.8	25
68	COVID-19 first anniversary review of cases, hospitalization, and mortality in the UK. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 973-978.	1.0	8
69	Could it be that the B.1.1.7 lineage is more deadly?. <i>Infection Control and Hospital Epidemiology</i> , 2021, , 1-1.	1.0	4
70	The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis. <i>Pharmacological Reports</i> , 2021, 73, 1473-1479.	1.5	25
71	Do sleep quality and sleep duration before or after COVID-19 vaccination affect antibody response?. <i>Chronobiology International</i> , 2021, 38, 941-943.	0.9	10
72	Adverse Drug Reaction Reporting and Prescribing Trends of Drugs for Attention Deficit Hyperactivity Disorder in Primary Care England, 2010-2019. <i>Journal of Attention Disorders</i> , 2021, , 108705472199755.	1.5	6

#	ARTICLE	IF	CITATIONS
73	Surging trends in prescriptions and costs of antidepressants in England amid COVID-19. <i>DARU, Journal of Pharmaceutical Sciences</i> , 2021, 29, 217-221.	0.9	56
74	Potential interactions between COVID-19 vaccines and antiepileptic drugs. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2021, 86, 80-81.	0.9	17
75	Association of frailty and mortality in patients with COVID-19: a meta-analysis. <i>British Journal of Anaesthesia</i> , 2021, 126, e108-e110.	1.5	13
76	Effect of COVID-19 on viral hepatitis services in Pakistan. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 163-164.	3.7	4
77	Worldwide Survey of COVID-19-associated Arrhythmias. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009458.	2.1	127
78	Intensive blood pressure-lowering strategy should also be offered to older patients. <i>Journal of Hypertension</i> , 2021, 39, 812-813.	0.3	1
79	The risk of mortality in patients with COVID-19 with pre-diagnosis use of NSAIDs: a meta-analysis. <i>Inflammopharmacology</i> , 2021, 29, 641-644.	1.9	13
80	The coincidence of increased risk of atrial fibrillation in randomized control trials of omega-3 fatty acids: a meta-analysis. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 773-775.	1.3	4
81	Use of antiplatelet drugs and the risk of mortality in patients with COVID-19: a meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 124-129.	1.0	28
82	Interferon-based therapies in COVID-19. <i>International Immunopharmacology</i> , 2021, 93, 107415.	1.7	4
83	Cerebral venous thrombosis following COVID-19 vaccination. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105866.	0.7	1
84	Antimicrobial consumption among hospitalized patients with COVID-19 in Pakistan. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 1691-1695.	0.3	36
85	Pharmacist-patient communication amid COVID-19 pandemic: A review of available options and potential impact. <i>British Journal of Pharmacy</i> , 2021, 6, .	0.1	4
86	Corticosteroid Plus Tocilizumab in COVID-19. <i>Chest</i> , 2021, 159, 2108-2109.	0.4	1
87	Renin-angiotensin system inhibitor use and the risk of mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials. <i>Hypertension Research</i> , 2021, 44, 1042-1045.	1.5	11
88	Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19. <i>Mayo Clinic Proceedings</i> , 2021, 96, 1365-1367.	1.4	3
89	Special consideration in the dosing of medications for patients with COVID-19 and acute kidney injury. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2021, 47, 690-691.	0.7	0
90	Quality of clinical practice guidelines for the management of hypertension in six Southeast Asian countries. <i>Clinical and Experimental Hypertension</i> , 2021, 43, 633-641.	0.5	1

#	ARTICLE	IF	CITATIONS
91	Mortality risk in patients infected with SARS-CoV-2 of the lineage B.1.1.7 in the UK. <i>Journal of Infection</i> , 2021, 83, e14-e15.	1.7	13
92	Does methylprednisolone reduce the mortality risk in hospitalized COVID-19 patients? A meta-analysis of randomized control trials. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1049-1055.	1.0	17
93	Concordance of recommendations across clinical practice guidelines for the management of hypertension in Southeast Asia with internationally reputable sources. <i>BMC Cardiovascular Disorders</i> , 2021, 21, 354.	0.7	3
94	Real-world effectiveness of BNT162b2 mRNA vaccine: a meta-analysis of large observational studies. <i>Inflammopharmacology</i> , 2021, 29, 1075-1090.	1.9	55
95	A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19. <i>Therapie</i> , 2021, 76, 361-364.	0.6	10
96	Pitfalls in Reporting Sample Size Calculation Across Randomized Controlled Trials Involving Ivermectin for the treatment of COVID-19. <i>American Journal of Therapeutics</i> , 2021, 28, e616-e619.	0.5	4
97	An overview of procurement, pricing, and uptake of COVID-19 vaccines in Pakistan. <i>Vaccine</i> , 2021, 39, 5251-5253.	1.7	11
98	Lactoferrin reduces the risk of respiratory tract infections: A meta-analysis of randomized controlled trials. <i>Clinical Nutrition ESPEN</i> , 2021, 45, 26-32.	0.5	18
99	Statin use in patients with diabetes amid COVID-19 pandemic. <i>Diabetes and Metabolism</i> , 2021, 48, 101298.	1.4	1
100	Ingestion of beta-glucans could stimulate longer-lasting cellular immunity upon administration of COVID-19 vaccines. <i>Journal of Food Biochemistry</i> , 2021, 45, e13959.	1.2	0
101	Prevalence of frailty in patients with COVID-19: a meta-analysis. <i>Journal of Frailty &amp; Aging</i> , 2021, 10, 1-2.	0.8	5
102	Colchicine for COVID-19: Hype or hope?. <i>European Journal of Internal Medicine</i> , 2021, , .	1.0	1
103	Use of rituximab and the risk of adverse clinical outcomes in COVID-19 patients with systemic rheumatic disease. <i>Rheumatology International</i> , 2020, 40, 2117-2118.	1.5	25
104	Use of hydroxychloroquine and chloroquine in COVID-19: How good is the quality of randomized controlled trials?. <i>International Journal of Infectious Diseases</i> , 2020, 101, 107-120.	1.5	9
105	The Potential Benefit of Telmisartan to Protect Overweight Patients with COPD from the Acquisition of COVID-19. <i>Obesity</i> , 2020, 28, 2035-2035.	1.5	1
106	Anticoagulant approach in COVID-19 patients with cerebral venous thrombosis. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 105222.	0.7	9
107	Do the Meta-Analyses Provide a Clean Bill of Health to the Use of Renin-angiotensin System Inhibitors in Coronavirus Disease 2019 (COVID-19)?. <i>Clinical Infectious Diseases</i> , 2020, 73, 164-165.	2.9	0
108	Montelukast in children with allergic rhinitis amid COVID-19 pandemic. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2020, 109, 2151-2151.	0.7	3

#	ARTICLE	IF	CITATIONS
109	Pharmacotherapeutic considerations for the management of cardiovascular diseases among hospitalized COVID-19 patients. <i>Expert Review of Cardiovascular Therapy</i> , 2020, 18, 475-485.	0.6	4
110	Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 1149-1163.	1.0	184
111	Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 814-821.	1.0	92
112	Meta-analysis of Effect of Statins in Patients with COVID-19. <i>American Journal of Cardiology</i> , 2020, 134, 153-155.	0.7	149
113	The Use of Pharmacological Preventive Therapy for Migraine With Weight Gain Potential Amid Coronavirus Disease 2019 Pandemic. <i>Headache</i> , 2020, 60, 2085-2086.	1.8	0
114	Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 571-590.	1.0	34
115	Use of Azithromycin in COVID-19: A Cautionary Tale. <i>Clinical Drug Investigation</i> , 2020, 40, 989-990.	1.1	10
116	Pharmacotherapeutic considerations for systemic rheumatic diseases amid the COVID-19 pandemic: more questions than answers. <i>Drugs and Therapy Perspectives</i> , 2020, 36, 518-522.	0.3	1
117	Optimal time for the resumption of biologics after COVID-19. <i>JAAD International</i> , 2020, 1, 189.	1.1	1
118	Glucocorticoid versus immunoglobulin in the treatment of COVID-19-associated fulminant myocarditis. <i>Infection</i> , 2020, 48, 805-806.	2.3	12
119	Use of corticosteroids in asthma and COPD patients with or without COVID-19. <i>Respiratory Medicine</i> , 2020, 170, 106045.	1.3	32
120	Vitamin D Supplementation in Influenza and COVID-19 Infections Comment on: "Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths" • <i>Nutrients</i> 2020, 12(4), 988. <i>Nutrients</i> , 2020, 12, 1626.	1.7	20
121	Use of statins in patients with COVID-19. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2020, 113, 604-605.	0.2	4
122	Management of Outpatient Warfarin Therapy amid COVID-19 Pandemic: A Practical Guide. <i>American Journal of Cardiovascular Drugs</i> , 2020, 20, 301-309.	1.0	24
123	Metformin use amid coronavirus disease 2019 pandemic. <i>Journal of Medical Virology</i> , 2020, 92, 2401-2402.	2.5	12
124	Use of low-molecular-weight heparin in COVID-19 patients. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2020, 8, 900-901.	0.9	24
125	Role of frailty in COVID-19 patients. <i>Intensive Care Medicine</i> , 2020, 46, 1956-1957.	3.9	3
126	Possible Protective Effect of Renin-Angiotensin System Inhibitors in COVID-19 Induced Acute Kidney Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1917-1918.	3.0	4

#	ARTICLE	IF	CITATIONS
127	Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19. American Journal of Cardiovascular Drugs, 2020, 20, 217-221.	1.0	23
128	Dexamethasone or hydrocortisone in COVID-19?. Cleveland Clinic Journal of Medicine, 2020, 87, 715-715.	0.6	9
129	Is it worth the wait? Should Chloroquine or Hydroxychloroquine be allowed for immediate use in CoViD-19?. British Journal of Pharmacy, 2020, 5, .	0.1	2
130	Smoking Cessation Amid the Coronavirus 2019 Pandemic: Making Every Contact Count. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2020, 7, 300-302.	0.5	1
131	Use of Pharmacologic Agents With Weight Gain Potential for Panic Disorder Amid the COVID-19 Pandemic. primary care companion for CNS disorders, The, 2020, 22, .	0.2	0
132	Economic evaluation of pharmacist-led medication reviews in residential aged care facilities. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 431-439.	0.7	17
133	Metformin therapy in COVID-19: inhibition of NETosis. Journal of Thrombosis and Thrombolysis, 0, , .	1.0	1
134	The use of corticosteroids in patients with COVID-19 vaccine-related cerebral venous thrombosis. Neurological Sciences, 0, , .	0.9	1